Cargando…

Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap

Sickle cell trait (SCT) has historically been considered a benign condition, but SCT-positive patients have increased baseline risk of venous thromboembolism and chronic kidney disease, as well as increased risk of sickled erythrocytes in settings of hypoxia, acidosis, and hypovolemia. Multisystem t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessema, Frazer A, Lapping-Carr, Gabrielle, Affini, Murtala I, Selkridge, Isaiah K, Oppong, Akosua Y, Jones, Tanisha A, Zakrison, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171217/
https://www.ncbi.nlm.nih.gov/pubmed/35719190
http://dx.doi.org/10.1136/tsaco-2022-000955
_version_ 1784721616604758016
author Tessema, Frazer A
Lapping-Carr, Gabrielle
Affini, Murtala I
Selkridge, Isaiah K
Oppong, Akosua Y
Jones, Tanisha A
Zakrison, Tanya
author_facet Tessema, Frazer A
Lapping-Carr, Gabrielle
Affini, Murtala I
Selkridge, Isaiah K
Oppong, Akosua Y
Jones, Tanisha A
Zakrison, Tanya
author_sort Tessema, Frazer A
collection PubMed
description Sickle cell trait (SCT) has historically been considered a benign condition, but SCT-positive patients have increased baseline risk of venous thromboembolism and chronic kidney disease, as well as increased risk of sickled erythrocytes in settings of hypoxia, acidosis, and hypovolemia. Multisystem traumatic injuries are a common clinical scenario, in which hypoxia, acidosis, and hypovolemia occur; however, little is known about how SCT-positive status impacts outcomes in multisystem trauma. We conducted a scoping literature review to investigate what was known about SCT in the setting of multisystem trauma. In the 110+ years that sickle cell hemoglobinopathies have been known, only three studies have ever examined the relationship between SCT and multisystem traumas. All three articles were case reports. None of the articles intentionally measured the association between SCT and multisystem trauma outcomes; they only incidentally captured information on SCT. Our article then examines historical reasons why so little research has studied the pathophysiology of the multisystem trauma in patients with SCT. Among the reasons is that historical and logistical factors have long prevented patients from knowing their SCT-status: historical discriminations against SCT-positive patients in the 1960s and 1970s delayed federal mandating of SCT newborn screening until 2006, whereas difficulties communicating known SCT-status to afflicted children also contributed to lack of patient knowledge. In light of our findings, we offer specific calls to action for the trauma surgery research community: (1) consider testing for SCT in trauma patients that have unexpected complications, particularly venous thromboembolism, rhabdomyolysis, or renal failure and (2) support research to understand how SCT impacts multisystem trauma outcomes. We also offer specific guidelines about how to ‘proceed with caution’ in implementation of these goals in light of the troubled history of SCT testing and policy in the USA.
format Online
Article
Text
id pubmed-9171217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91712172022-06-16 Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap Tessema, Frazer A Lapping-Carr, Gabrielle Affini, Murtala I Selkridge, Isaiah K Oppong, Akosua Y Jones, Tanisha A Zakrison, Tanya Trauma Surg Acute Care Open Current Opinion Sickle cell trait (SCT) has historically been considered a benign condition, but SCT-positive patients have increased baseline risk of venous thromboembolism and chronic kidney disease, as well as increased risk of sickled erythrocytes in settings of hypoxia, acidosis, and hypovolemia. Multisystem traumatic injuries are a common clinical scenario, in which hypoxia, acidosis, and hypovolemia occur; however, little is known about how SCT-positive status impacts outcomes in multisystem trauma. We conducted a scoping literature review to investigate what was known about SCT in the setting of multisystem trauma. In the 110+ years that sickle cell hemoglobinopathies have been known, only three studies have ever examined the relationship between SCT and multisystem traumas. All three articles were case reports. None of the articles intentionally measured the association between SCT and multisystem trauma outcomes; they only incidentally captured information on SCT. Our article then examines historical reasons why so little research has studied the pathophysiology of the multisystem trauma in patients with SCT. Among the reasons is that historical and logistical factors have long prevented patients from knowing their SCT-status: historical discriminations against SCT-positive patients in the 1960s and 1970s delayed federal mandating of SCT newborn screening until 2006, whereas difficulties communicating known SCT-status to afflicted children also contributed to lack of patient knowledge. In light of our findings, we offer specific calls to action for the trauma surgery research community: (1) consider testing for SCT in trauma patients that have unexpected complications, particularly venous thromboembolism, rhabdomyolysis, or renal failure and (2) support research to understand how SCT impacts multisystem trauma outcomes. We also offer specific guidelines about how to ‘proceed with caution’ in implementation of these goals in light of the troubled history of SCT testing and policy in the USA. BMJ Publishing Group 2022-06-05 /pmc/articles/PMC9171217/ /pubmed/35719190 http://dx.doi.org/10.1136/tsaco-2022-000955 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Current Opinion
Tessema, Frazer A
Lapping-Carr, Gabrielle
Affini, Murtala I
Selkridge, Isaiah K
Oppong, Akosua Y
Jones, Tanisha A
Zakrison, Tanya
Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title_full Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title_fullStr Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title_full_unstemmed Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title_short Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
title_sort sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171217/
https://www.ncbi.nlm.nih.gov/pubmed/35719190
http://dx.doi.org/10.1136/tsaco-2022-000955
work_keys_str_mv AT tessemafrazera sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT lappingcarrgabrielle sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT affinimurtalai sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT selkridgeisaiahk sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT oppongakosuay sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT jonestanishaa sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap
AT zakrisontanya sicklecelltraitandmultisystemtraumaanunaddressedurgentknowledgegap